Clinical Trials

9 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Bronchial Neoplasms × Clear all
NCT04774952 2025-04-15

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Revolution Medicines, Inc.

Phase 1 Completed
58 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Neoplasms, Squamous Cell

NCT05462717 2024-11-07

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Revolution Medicines, Inc.

Phase 1 Active not recruiting
222 enrolled
GastrointestinalGynecologicThoracic

Appendiceal Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Stomach Neoplasms, Thoracic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Pancreatic Ductal

NCT03634982 2022-09-01

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Revolution Medicines, Inc.

Phase 1 Unknown
133 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Noonan Syndrome, Ovarian Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Neoplasms, Squamous Cell

NCT02897778 2022-04-28

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Syndax Pharmaceuticals

Phase 1 Completed
30 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Digestive System Neoplasms, Endocrine Gland Neoplasms, Kidney Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02909452 2022-01-25

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Syndax Pharmaceuticals

Phase 1 Completed
30 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Diseases, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Digestive System Neoplasms, Endocrine Gland Neoplasms, Kidney Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Respiratory Tract Neoplasms, Thoracic Neoplasms